Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 3;5(11):1034-1043.
doi: 10.1002/bco2.440. eCollection 2024 Nov.

Indian consensus statements on the management of small renal masses, non-muscle invasive bladder cancer and high-risk/locally advanced prostate cancer

Simon Hughes  1   2   3 , Rajesh Nair  4 , Bhav Radia  5 , Ravimohan S Mavuduru  4 , Prokar Dasgupta  3   4 , Amit Ghose  6
Affiliations

Indian consensus statements on the management of small renal masses, non-muscle invasive bladder cancer and high-risk/locally advanced prostate cancer

Simon Hughes et al. BJUI Compass. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. eCollection 2024 Dec. BJUI Compass. 2024. PMID: 39744071 Free PMC article.

Abstract

No pan-India-specific guidelines exist for the management of urological cancers. Although western guidelines are useful for informing management strategies, they do not account for the nuances of management in the Indian context. A modified Delphi method was used to provide a framework for the systematic development of India-centric guidelines for the management of three uro-oncology disease states: small renal masses, non-muscle invasive bladder cancer and high-risk/locally advanced prostate cancer.

Keywords: India; consensus; high‐risk prostate cancer; non‐muscle invasive bladder cancer; small renal masses.

PubMed Disclaimer

Conflict of interest statement

Simon Hughes: Honoraria/travel grants from Astellas, Janssen, Bayer. Prokar Dasgupta: Proximie, MysteryVibe. The other authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Modified Delphi flow chart.
FIGURE 2
FIGURE 2
A heat map to display the geographical distribution of participants in the final consensus statement voting.
FIGURE 3
FIGURE 3
Example of a consensus voting slide (prostate cancer session).
See this image and copyright information in PMC

References

    1. Campbell SC, Clark PE, Chang SS, et al. Renal mass and localized renal cancer: evaluation, management, and follow up: AUA guideline parts 1 and 2. J Urol. 2021;206:199–208. - PubMed
    1. Ljungberg B, Bex A, Albiges L et al. EAU Guidelines on Renal Cell Carcinoma. 2024; https://uroweb.org/guidelines/renal-cell-carcinoma/publications-appendices
    1. FDA approves pembrolizumab for BCG‐unresponsive, high‐risk non‐muscle invasive bladder cancer. 2020; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...
    1. Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for high‐risk non‐muscle‐invasive bladder cancer unresponsive to BCG (Keynote‐057): a single arm, multicentre, phase 2 trial. Lancet Oncol. 2021;22(7):919–930. 10.1016/S1470-2045(21)00147-9 - DOI - PubMed
    1. Necchi A, Roumiguie M, Kamat A, et al. Pembrolizumab monotherapy for high‐risk non‐muscle‐invasive bladder cancer without carcinoma in situ and unresponsive to BCG (Keynote‐057): a single arm, multicentre, phase 2 trial. Lancet Oncol. 2004;25(6):720–730. - PubMed

LinkOut - more resources